Literature DB >> 18290728

Epidemiological evidence for vitamin D and colorectal cancer.

Edward Giovannucci1.   

Abstract

Since Garland and Garland formulated the hypothesis that vitamin D may protect against colorectal cancer in 1980, various epidemiological approaches have been undertaken to evaluate this hypothesis. These approaches include studies based on regional solar UVB radiation, plasma- or serum-based studies, dietary studies, and those examining multiple factors that influence vitamin D status. Studies over the past several decades have tended to support that higher levels of vitamin D may decrease risk of colorectal cancer. An important implication is that current recommended dietary intakes such as 200-400 IU/d may be too low to exert appreciable benefits. To substantially reduce risk, higher levels of vitamin D associated with sunshine exposure or considerably higher intakes may be required. Recent studies also suggest a potential benefit of vitamin D on other digestive system cancers. One study suggested that a better vitamin D status at the time of diagnosis and treatment, as indicated by season of diagnosis, may improve survival from colorectal cancer. Darker-skinned individuals who tend to make less vitamin D may be at particularly high risk for digestive system cancer. The strong biological evidence for a protective role of vitamin D supports the epidemiological data. More study is needed to determine the optimal levels and intakes of this vitamin to optimally reduce colorectal cancer risk.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18290728     DOI: 10.1359/jbmr.07s206

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  27 in total

1.  Vitamin D and autoimmune thyroid diseases.

Authors:  Shaye Kivity; Nancy Agmon-Levin; Michael Zisappl; Yinon Shapira; Endre V Nagy; Katalin Dankó; Zoltan Szekanecz; Pnina Langevitz; Yehuda Shoenfeld
Journal:  Cell Mol Immunol       Date:  2011-01-31       Impact factor: 11.530

2.  Prospective study of ultraviolet radiation exposure and risk of cancer in the United States.

Authors:  Shih-Wen Lin; David C Wheeler; Yikyung Park; Elizabeth K Cahoon; Albert R Hollenbeck; D Michal Freedman; Christian C Abnet
Journal:  Int J Cancer       Date:  2012-05-29       Impact factor: 7.396

Review 3.  Beyond standard adjuvant therapy for colon cancer: role of nonstandard interventions.

Authors:  Jeffrey A Meyerhardt
Journal:  Semin Oncol       Date:  2011-08       Impact factor: 4.929

4.  Serum 25-hydroxy vitamin D and survival in advanced colorectal cancer: a retrospective analysis.

Authors:  Kathleen M Wesa; Neil H Segal; Angel M Cronin; Daniel D Sjoberg; Gria N Jacobs; Marci I Coleton; Martin Fleisher; Ann M Dnistrian; Leonard B Saltz; Barrie R Cassileth
Journal:  Nutr Cancer       Date:  2015-02-03       Impact factor: 2.900

5.  Trout ova, an alternative source of anti-B.

Authors:  P Rees; R Cotton; P D Holt; D J Anstee
Journal:  Med Lab Sci       Date:  1976-01

6.  Serum 25-hydroxyvitamin D is inversely associated with body mass index in cancer.

Authors:  Pankaj G Vashi; Carolyn A Lammersfeld; Donald P Braun; Digant Gupta
Journal:  Nutr J       Date:  2011-05-16       Impact factor: 3.271

7.  Diabetes and thyroid cancer risk in the National Institutes of Health-AARP Diet and Health Study.

Authors:  Briseis Aschebrook-Kilfoy; Mona M Sabra; Alina Brenner; Steven C Moore; Elaine Ron; Arthur Schatzkin; Albert Hollenbeck; Mary H Ward
Journal:  Thyroid       Date:  2011-07-18       Impact factor: 6.568

8.  Variation in the vitamin D receptor gene is not associated with risk of colorectal cancer in the Czech Republic.

Authors:  David J Hughes; Ivona Hlavatá; Pavel Soucek; Barbara Pardini; Alessio Naccarati; Ludmila Vodickova; Mazda Jenab; Pavel Vodicka
Journal:  J Gastrointest Cancer       Date:  2011-09

9.  Parathormone and 1,25(OH)2D3 but not 25(OH)D3 serum levels, in an inverse correlation, reveal an association with advanced stages of colorectal cancer.

Authors:  Anestis Charalampopoulos; Alexander Charalabopoulos; Anna Batistatou; Christos Golias; Antonia Anogeianaki; Dimitrios Peschos; Iosif Iliadis; Anastasios Macheras; Konstantinos Charalabopoulos
Journal:  Clin Exp Med       Date:  2009-09-25       Impact factor: 3.984

10.  Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma.

Authors:  David E Leaf; Renata C Pereira; Hasan Bazari; Harald Jüppner
Journal:  J Clin Endocrinol Metab       Date:  2013-02-07       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.